Prevalence of Sars-Cov-2-IgG in HIV-infected pople B20-B24 U07.1
Conditions
Interventions
Group 1: The prevalence of SARS-CoV-2 antibodies will be evaluated in 500 consecutive patients already participating in the ArcHIV (DRKS00021737) observational study.
A CE-certified test is used for t
Sponsors
MUC Research GmbH
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patient is already a study participant in ArcHIV, the signed patient information with consent and privacy declaration for this substudy
Exclusion criteria
Exclusion criteria: Patient is not a study participant of the study platform ArcHIV, patient <18 years, Patient has no present signed consent and privacy statement of the substudy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary goal of the ArcHIV substudy is to evaluate the presence of IgG antibodies against SARS-CoV-2 - as a prevalence estimate of previous infections - in an HIV population. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary objectives are the description of SARS-CoV-2-IgG prevalence with regard to SARS-CoV-2 anamnesis (already proven SARS-CoV-2 infections) or the known SARS-CoV-2 exposure in this HIV cohort and the description of HIV-specific characteristics including antiretroviral therapy | — |
Countries
Germany
Contacts
Public ContactSebastian Noe
MVZ Karlsplatz
Outcome results
None listed